PHYRAGO™ is the first and only dasatinib product that can be co-administered with gastric acid-reducing agents. An estimated one-third of patients who require SPRYCEL ® treatment may also take gastric ...

Off-label dasatinib induced symptomatic and partial hematologic response, enabling successful curative-intent transplantation in an aggressive SM subtype.

Hospital Authority says it began subsidising Dasatinib in April, with patients previously paying up to HK$500,000 annually ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- After receiving a priority review, Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug ...

Rakesh Jain Ph.D., Director of the E.L. Steele Laboratories for Tumor Biology at Massachusetts General Hospital and A. Werk Cook Professor of Radiation Oncology at Harvard Medical School, is senior ...

From Clinical Trials to Practice: Anticipating and Overcoming Challenges in Implementing Watch-and-Wait for Rectal Cancer Clinical trials frequently include multiple end points that mature at ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome–positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones ...

We describe two cases of panniculitis apparently caused by dasatinib. In one, management after the diagnosis of the panniculitis allowed dasatinib therapy to be continued. In the first case, a 55-year ...

STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of ...